Myriad Genetics (MYGN) FDA Approvals $3.64 -0.09 (-2.28%) Closing price 03:59 PM EasternExtended Trading$3.62 -0.02 (-0.69%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Myriad Genetics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Myriad Genetics (MYGN). Over the past two years, Myriad Genetics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as niraparib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Niraparib FDA Regulatory Events Niraparib is a drug developed by Myriad Genetics for the following indication: patients with advanced ovarian cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA approved - March 17,2026Fda Approved Drug: niraparibAnnounced Date: March 17, 2026Indication: patients with advanced ovarian cancer.AnnouncementMyriad Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.AI SummaryMyriad Genetics announced that the U.S. Food and Drug Administration has approved the MyChoice® CDx Test as the companion diagnostic for Zejula® (niraparib), GSK’s PARP inhibitor, for patients with advanced ovarian cancer. The approval allows MyChoice CDx to be used to identify patients whose tumors show homologous recombination deficiency (HRD), helping clinicians determine who is likely to benefit from Zejula treatment. Myriad said the decision highlights its leadership in ovarian cancer diagnostics and the clinical value of broad HRD testing. Nearly half of patients with advanced ovarian cancer have HRD-positive tumors, so identifying these patients is key to choosing appropriate PARP inhibitor therapy and personalizing treatment plans. By providing robust genomic information, MyChoice CDx aims to guide treatment decisions and improve matching of patients to targeted therapy.Read Announcement Myriad Genetics FDA Events - Frequently Asked Questions Has Myriad Genetics received FDA approval? As of now, Myriad Genetics (MYGN) has not received any FDA approvals for its therapy in the last two years. What drugs has Myriad Genetics submitted to the FDA? In the past two years, Myriad Genetics (MYGN) has reported FDA regulatory activity for niraparib. What is the most recent FDA event for Myriad Genetics? The most recent FDA-related event for Myriad Genetics occurred on March 17, 2026, involving niraparib. The update was categorized as "FDA approved," with the company reporting: "Myriad Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer." What conditions do Myriad Genetics' current drugs treat? Currently, Myriad Genetics has one therapy (niraparib) targeting the following condition: patients with advanced ovarian cancer.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsApyx Medical FDA EventsAtossa Genetics FDA EventsBiogen FDA EventsBioLineRx FDA EventsCAMP4 Therapeutics FDA EventsCelcuity FDA EventsClimb Bio FDA EventsCorvus Pharmaceuticals FDA EventsEditas Medicine FDA EventsEyepoint Pharmaceuticals FDA EventsGenprex FDA EventsGT Biopharma FDA EventsMiNK Therapeutics FDA EventsINmune Bio FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Innoviva FDA Events Novavax FDA Events Zenas BioPharma FDA Events Geron FDA Events MannKind FDA Events OPKO Health FDA Events Lexicon Pharmaceuticals FDA Events Rigel Pharmaceuticals FDA Events Verastem FDA Events Crescent Biopharma FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:MYGN last updated on 3/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersOne coin wired into Elon's visionThe SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...Crypto 101 Media | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredTengu is coming (prepare for June 16)A data leak exposed the code name of an AI breakthrough called Project Tengu - and in just six days, it erased...Chaikin Analytics | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approved - March 17,2026Fda Approved Drug: niraparibAnnounced Date: March 17, 2026Indication: patients with advanced ovarian cancer.AnnouncementMyriad Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.AI SummaryMyriad Genetics announced that the U.S. Food and Drug Administration has approved the MyChoice® CDx Test as the companion diagnostic for Zejula® (niraparib), GSK’s PARP inhibitor, for patients with advanced ovarian cancer. The approval allows MyChoice CDx to be used to identify patients whose tumors show homologous recombination deficiency (HRD), helping clinicians determine who is likely to benefit from Zejula treatment. Myriad said the decision highlights its leadership in ovarian cancer diagnostics and the clinical value of broad HRD testing. Nearly half of patients with advanced ovarian cancer have HRD-positive tumors, so identifying these patients is key to choosing appropriate PARP inhibitor therapy and personalizing treatment plans. By providing robust genomic information, MyChoice CDx aims to guide treatment decisions and improve matching of patients to targeted therapy.Read Announcement
